US Treasury 3 Year Note ETF UTRE 深 滬
等待開盤 09-20 09:30:00 美东时间
50.0227
+0.043
+0.09%
華盛通- 最 高50.03
- 今 開49.99
- 成交量 5025股
- 最 低 49.99
- 昨 收 49.9801
- 總市值 750.34万
- 52周最高 50.09
- 市盈率 靜 --
- 換手率 3.35%
- 52周最低 46.3149
- 委 比 0.00%
- 總股本 15.00万
- 歷史最高 50.09
- 量 比 1.49
- 振 幅 0.08%
- 歷史最低 46.3149
- 每 手 1
- 風險率 0.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Liquidia challenges exclusivity blocking Yutrepia in new lawsuit
Liquidia Corporation (NASDAQ:LQDA) announced Thursday a lawsuit challenging the recent FDA decision to grant a three-year exclusivity to Tyvaso DPI from United Therapeutics (UTHR), which it said had d...
08-22 20:39
These Analysts Cut Their Forecasts On Liquidia
Liquidia Corporation (NASDAQ:LQDA), on Monday, announced that the Food and Drug...
08-20 20:15
Market-Moving News for August 19th
ALZN: 248% | Alzamend Neuro Partners With Massachusetts General Hospital For First-of-Its-Kind Phase II Study Of AL001 For PTSD Treatment ZIM: 18% | ZIM Integrated Shipping Services shares are trading
08-19 20:36
Expert Ratings For Liquidia
During the last three months, 6 analysts shared their evaluations of Liquidia (...
08-08 20:02
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on M...
06-03 22:39
Liquidia Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
In the last three months, 6 analysts have published ratings on Liquidia (NASDAQ...
05-15 20:01
The Analyst Landscape: 5 Takes On Liquidia
Liquidia (NASDAQ:LQDA) has been analyzed by 5 analysts in the last three months...
04-02 02:00
Unveiling 6 Analyst Insights On Liquidia
6 analysts have expressed a variety of opinions on Liquidia (NASDAQ:LQDA) over ...
03-14 05:00
S&P Global Sustainable1 announced as Principal Founding Data Partner to PCAF
UTRECHT, Netherlands and NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Partnership for Carbon Accounting Financials (PCAF) and S&P Global Sustainable1 announced today that S&P Global Sustainab...
02-28 21:00
Merus Announces Business Update Conference Call
Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and...
2023-10-16 07:58
